ClinicalTrials.gg
CompletedNCT05280067ZGMBCUpdated Jan 16, 2026

ZETAMET™ BONE GRAFT IN THE REPAIR OF BONE DEFECTS FROM METASTATIC BREAST CANCER IN VERTEBRAL BONES

A Phase 2 interventional study of ZetaMet™ (ZetaFuse™ Bone Graft) in Metastatic Breast Cancer in the Spine, sponsored by Zetagen Therapeutics, Inc. Completed at 2 sites in Canada. Open to female participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-01-16.

Sponsored by Zetagen Therapeutics, Inc · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
22 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 907 studies in Breast Neoplasms with a site in Canada — 139 open to participants now, 257 under way, 81 of them phase 3. Breast Neoplasms · Canada.

Enrollment
749th of 787
10 · median 155
Started
2022
with 26 others
Phase 2
180 of 907
19 open now
Registered
747th of 907
by date

Among the 907 studies in Breast Neoplasms with a site in Canada, this one is the 749th largest by enrollment of the 787 interventional ones that give a count, is one of 27 that started in 2022, is one of 180 in phase 2, and was the 747th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

139 of the 907 studies in Breast Neoplasms with a site in Canada are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 22 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 907 studies in Breast Neoplasms with a site in Canada, or all of them as a file.
02

Study summary

ZetaMet™ is indicated for patients with destructive, lytic lesions due to metastatic breast cancer to bone, with or without involvement of other sites, with at least one metastatic lesion located in a vertebral body of the spine, and a Spinal Instability Neoplastic Score (SINS) ≥3 and ≤9. ZetaMet™ is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. ZetaMet™ is only for implantation into the vertebral body.

Read the detailed description

This is an open-label single-arm study. Subjects (N=10) will be recruited from up to 4 Investigational Sites in Canada. Key inclusion criteria are metastatic breast cancer to bone with at least one lytic metastatic lesion located in a vertebral body of the spine and a SINS ≥3 and ≤9. ZetaMet™ will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor. Post-operative care will be per standard of care (SOC) at the Investigational Site. Subjects will be followed for 180 days post-treatment. If post-surgical radiation treatment is planned, it should not occur for at least 84 days post-surgery to allow for bone formation.

03

Conditions studied

  • Metastatic Breast Cancer in the Spine

Browse trials for

Keywords

  • Metastatic Breast Cancer
  • Bone Metastases
  • Spine Metastases
  • Vancouver
  • Metastatic Breast Cancer to Bone
  • X-radiation therapy
04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 22 (inclusive) and 75 years (inclusive) at the time of enrollment.
  • of 12 months or more.
  • Female patient with confirmed diagnosis of primary breast cancer.
  • breast cancer to bone, with or without involvement of other sites (patients with single metastasis qualify)
  • At least one lytic metastatic lesion located in the vertebral body of the spine.
  • Normal spinal alignment.
  • SINS ≥3 and ≤9.
  • Signed and dated Form (ICF).
  • Patient is willing and able to participate in required follow-up visits at the Site and to complete study procedures and questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Vertebral body collapse.
  • Spinal cord compression.
  • Known allergy to Device materials.
  • Using medications or any drug known to potentially interfere with bone/soft tissue healing (e.g., chronic systemic ).
  • Current tobacco smoker or stopped smoking in past 6 months.
  • Uncontrolled diabetes mellitus, HbAIC cutoff.
  • An active systemic infection (e.g., hepatitis, acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC).
  • Currently participating in any investigational trial not related to this trial.
  • Any other severe acute or chronic medical condition that may interfere with the interpretation of the trial results, in the judgment of the PI, which would make the patient inappropriate for entry into this trial.
  • Pregnant or planning to become pregnant during the trial.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Investigational Device ZetaMet™

    ZetaMet™ is percutaneously implanted into the bone defect created by the metastatic tumor in a spinal vertebral body. ZetaMet™ is only for implantation into the vertebral body.

    Combination Product: ZetaMet™ (ZetaFuse™ Bone Graft)

Interventions

  • Combination productZetaMet™ (ZetaFuse™ Bone Graft)

    ZetaMet™ (ZetaFuse™ Bone Graft) will be percutaneously implanted into the vertebral body defect(s) created by the lytic metastatic tumor.

06

What researchers measure

Primary outcomes

  1. Number of Skeletal Related Events (SREs)

    SREs include pathologic fracture, spinal cord compression, radiation therapy to bone, or surgical intervention.

    Time frame: Day 0 up to Day 180

  2. Number of subjects with at least one adverse event (AE)

    An AE is any unfavorable sign, symptom, or disease temporally associated with study participation, including the use of the Investigational Device and all study procedures. An AE may or may not be related to the use of the Investigational Device or a study procedure. AEs may include abnormal laboratory findings, radiologic events, medical complications, and changes from baseline in the subject's condition.

    Time frame: Day 0 up to Day 180

  3. Number of subjects with at least one procedure-related AE

    A procedure-related AE is any unfavorable sign, symptom, or disease temporally associated with any study procedure. These AEs may include abnormal laboratory findings, radiologic events, medical complications, and changes from baseline in the subject's condition, related to any study procedure.

    Time frame: Day 0 up to Day 180

  4. Number of subjects with at least one device-related AE

    A device-related AE is any unfavorable sign, symptom, or disease temporally associated with the Investigational Device. These AEs may include abnormal laboratory findings, radiologic events, medical complications, and changes from baseline in the subject's condition, related to the Investigational Device.

    Time frame: Day 0 up to Day 180

  5. Change in SINS assessment at 21 days compared to baseline

    The SINS is a scoring system based on six parameters; one for pain and five radiographic parameters (location, bone lesion quality, spinal alignment, vertebral body collapse and involvement of posterolateral elements). The SINS ranges 0-18. Score in range 0-6 denote stability; 7-12 intermediate instability and 13-18 instability.

    Time frame: Day 0 to Day 21 postoperatively

  6. Change in SINS assessment at 42 days compared to baseline

    The SINS is a scoring system based on six parameters; one for pain and five radiographic parameters (location, bone lesion quality, spinal alignment, vertebral body collapse and involvement of posterolateral elements). The SINS ranges 0-18. Score in range 0-6 denote stability; 7-12 intermediate instability and 13-18 instability.

    Time frame: Day 0 to Day 42 postoperatively

  7. Change in SINS assessment at 84 days compared to baseline

    The SINS is a scoring system based on six parameters; one for pain and five radiographic parameters (location, bone lesion quality, spinal alignment, vertebral body collapse and involvement of posterolateral elements). The SINS ranges 0-18. Score in range 0-6 denote stability; 7-12 intermediate instability and 13-18 instability.

    Time frame: Day 0 to Day 84 postoperatively

  8. Change in SINS assessment at 180 days compared to baseline

    The SINS is a scoring system based on six parameters; one for pain and five radiographic parameters (location, bone lesion quality, spinal alignment, vertebral body collapse and involvement of posterolateral elements). The SINS ranges 0-18. Score in range 0-6 denote stability; 7-12 intermediate instability and 13-18 instability.

    Time frame: Day 0 to Day 180 postoperatively

  9. Change in Short Form 12v2 (SF-12v2) score compared to baseline

    The 12-Item Short Form Survey version 2 (SF-12v2) is a shortened version of the SF-36v2 designed to reduce respondent burden while achieving minimum standards of precision for purposes of group comparisons involving multiple health dimensions. The SF-12v2 is given at baseline and at 180 days postoperatively.

    Time frame: Day 0 to Day 180 postoperatively

  10. Change in Back-specific Numeric Rating Scale for Pain (Back NRS) at 21 days compared to baseline

    The Numeric Rating Scale (NRS) is a psychometric response scale which is commonly used in questionnaires and studies to measure the intensity of pain. In this study we will use a 11-point (0-10) scale where "0" denotes no pain and "10" is the worst imaginable pain.

    Time frame: Day 0 to Day 21 postoperatively

  11. Change in Back-specific Numeric Rating Scale for Pain (Back NRS) at 42 days compared to baseline

    The Numeric Rating Scale (NRS) is a psychometric response scale which is commonly used in questionnaires and studies to measure the intensity of pain. In this study we will use a 11-point (0-10) scale where "0" denotes no pain and "10" is the worst imaginable pain.

    Time frame: Day 0 to Day 42 postoperatively

  12. Change in Back-specific Numeric Rating Scale for Pain (Back NRS) at 84 days compared to baseline

    The Numeric Rating Scale (NRS) is a psychometric response scale which is commonly used in questionnaires and studies to measure the intensity of pain. In this study we will use a 11-point (0-10) scale where "0" denotes no pain and "10" is the worst imaginable pain.

    Time frame: Day 0 to Day 84 postoperatively

  13. Change in Back-specific Numeric Rating Scale for Pain (Back NRS) at 180 days compared to baseline

    The Numeric Rating Scale (NRS) is a psychometric response scale which is commonly used in questionnaires and studies to measure the intensity of pain. In this study we will use a 11-point (0-10) scale where "0" denotes no pain and "10" is the worst imaginable pain.

    Time frame: Day 0 to Day 180 postoperatively

  14. Change in vertebral body defect size measured by CT at 42 days compared to baseline

    Vertebral body defect size measured by CT

    Time frame: Day 0 to Day 42 postoperatively

  15. Change in vertebral body defect size measured by planar radiographs at 42 days compared to baseline

    Vertebral body defect size and planar radiographs

    Time frame: Day 0 to Day 42 postoperatively

  16. Change in vertebral body defect size measured by CT at 180 days compared to baseline

    Vertebral body defect size measured by CT

    Time frame: Day 0 to Day 180 postoperatively

  17. Change in vertebral body defect size measured by planar radiographs at 180 days compared to baseline

    Vertebral body defect size measured by planar radiographs

    Time frame: Day 0 to Day 180 postoperatively

  18. Duration of use of postoperative prescription opioid

    The average per group duration of intake of opioids in the post-operative setting.

    Time frame: Day 180 postoperatively

  19. Daily dose of postoperative prescription opioid use

    The average per group dosage of opioids in the post-operative setting.

    Time frame: Day 180 postoperatively

  20. Naloxone concentrations in blood collected from patients at 30 minutes following the vertebroplasty procedure

    Two blood samples (5 mL each) of whole blood are collected at 30 minutes following the placement of the surgical bandage (n=2 blood collections of a total of 10 mL per patient). When naloxone blood concentrations remain below 1.016-ng/mL, there is not a reduction in opioid analgesia

    Time frame: 30 minutes following the placement of the surgical bandage

  21. Naloxone concentrations in blood collected from patients at 60 minutes after the vertebroplasty procedure

    Two blood samples (5 mL each) will be collected at 60 minutes following the placement of the surgical bandage (n=2 blood collections of a total of 10 mL per patient). When naloxone blood concentrations remain below 1.016-ng/mL, there is not a reduction in opioid analgesia

    Time frame: 60 minutes following the placement of the surgical bandage

07

Study locations

2 sites
  • Vancouver Coastal Health Research Institute
    Vancouver, British Columbia V5Z 1M9, Canada
  • McGill University Health Center
    Montreal, Quebec H3G1A4, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Oct 2025, 37 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 37 months is close to that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2022
First posted
Mar 15, 2022
StartActual
Sep 1, 2022
Primary completionActual
Oct 10, 2025
CompletionActual
Oct 10, 2025
Last update
Jan 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05280067
Lead sponsor
Zetagen Therapeutics, Inc
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Sep 1, 2022
Primary completion
Oct 10, 2025
Completion
Oct 10, 2025
Last update
Jan 16, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion